Johnson & Johnson expands oncology portfolio with USD3B acquisition of Halda Therapeutics

USA—Johnson & Johnson (J&J) has finalized the acquisition of Halda Therapeutics, a clinical-stage biotechnology company, in a cash transaction valued at USD 3.05 billion.

This strategic purchase strengthens J&J’s oncology division by integrating Halda’s cutting-edge Regulated Induced Proximity Targeting Chimera (RIPTAC) platform, which focuses on developing oral therapies designed to selectively target and destroy cancer cells.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.

The therapy leverages the RIPTAC platform to deliver precision-targeted action against tumour cells, aiming to overcome key resistance mechanisms that often limit existing treatments.

Alongside this lead program, the deal also brings a portfolio of early-stage candidates under development for breast, lung, and other solid tumour types, all utilising the same innovative RIPTAC technology.

J&J stated that the platform’s ability to induce targeted protein proximity could pave the way for new therapeutic discoveries not only within oncology but potentially across other disease areas.

By integrating Halda’s technological capabilities and scientific expertise, the company aims to accelerate its mission of advancing next-generation targeted therapies.

The acquisition, which closed in 2025, is expected to have a short-term financial impact with J&J anticipating earnings dilution in the fourth quarter of 2025 and continuing into 2026.

 The company projects a total effect of approximately USD 0.20 per share on adjusted earnings, evenly distributed over the two years.

This impact includes charges tied to Halda employee equity, financing, and integration costs.

Jennifer Taubert, worldwide chairman and executive vice president of J&J Innovative Medicine, highlighted that this milestone reinforces the company’s commitment to transforming cancer treatment through innovative science and transformative medicines.

She also expressed her enthusiasm for welcoming the Halda Therapeutics team, emphasizing J&J’s intent to work collaboratively toward their shared goal of ultimately eliminating cancer.

John Reed, executive vice president of J&J Innovative Medicine Research & Development, noted that with the acquisition now complete, the focus will shift toward advancing Halda’s promising pipeline of novel product candidates.

He added that J&J intends to fully harness the RIPTAC platform to identify and develop new molecules both within oncology and potentially in other therapeutic areas.

The acquisition follows J&J’s definitive agreement signed in November 2025, marking a significant step in the company’s long-term effort to expand its scientific capabilities and deliver next-generation treatment solutions for patients worldwide.